A deeper understanding of the heterogeneous nature of MASLD has recently contributed to the discovery of novel groups of agents and the potential repurposing of currently available medications
They also improve insulin release and blood glucose control, providing additional benefits for overall metabolic health
Retatrutide also incorporates structural modifications that influence receptor selectivity and signaling behavior across GLP 1, GIP, and glucagon receptor pathways
Dehydration risk, pancreatitis history, diabetic retinopathy, and rapid weight loss also warrant closer monitoring
Blood Sugar Effects Both medications improve glucose metabolism: Liraglutide: HbA1c reduction of 0.5-1.0% at weight loss doses Originally developed for diabetes (Victoza) Modest glucose benefits at Saxenda doses Semaglutide: HbA1c reduction of 1.0-1.8% at diabetes doses Greater glucose improvement than liraglutide Significant benefit for prediabetes and diabetes For patients with diabetes or prediabetes, semaglutide provides greater metabolic benefit
Approval: 2017 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning (2023)
